Alteogen, ALT-B4 US Substance Patent Registered

[Financial News] Alteogen announced on the 17th that the registration of a US substance patent for its independently developed hyaluronidase ALT-B4 has been confirmed.
It was notified of the patent registration through a local US patent agent, and the official patent number is US 12,371,683. The patent will be formally registered with the US Patent Office on the 29th and the patent rights will be maintained until early 2043.
ALT-B4 is an enzyme based on Alteogen's Hybrozyme platform. It hydrolyzes the hyaluronic acid layer in subcutaneous tissue, allowing blockbuster drugs previously administered via intravenous injection (IV) to be converted into subcutaneous injection (SC) formulations.
This is expected to offer advantages such as patent extension, improved treatment convenience, and reduced side effects, attracting the attention of global pharmaceutical companies.
This US patent registration was finalized after receiving a Notice of Allowance (NOA) from the US Patent Office earlier this year, followed by the payment of registration fees and subsequent examination procedures on the 5th.
An Alteogen representative stated, "Intellectual property (IP) in the bio industry is key to proving the value of technology," adding, "With this registration, which officially recognizes the novelty and inventiveness of Alteogen's ALT-B4 by the US Patent Office, we will further expand cooperation with global partners."
Currently, Alteogen has signed technology transfer agreements with six global pharmaceutical companies for the development of subcutaneous injection formulations based on Hybrozyme technology.
With this patent registration securing exclusive status in the US market, Alteogen plans to actively pursue IP protection and extension of exclusivity for partners and potential collaborators through ongoing patent strategies.

vrdw88@fnnews.com Kang Jung-mo Reporter